Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $45.00 at Mizuho

Enliven Therapeutics (NASDAQ:ELVN) had its target price increased by Mizuho from $41.00 to $45.00 in a report published on Wednesday,Benzinga reports. Mizuho currently has an outperform rating on the stock.

ELVN has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Enliven Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $41.80.

Enliven Therapeutics Price Performance

ELVN opened at $35.53 on Wednesday. Enliven Therapeutics has a 12 month low of $13.30 and a 12 month high of $36.72. The business has a 50-day moving average of $28.04 and a two-hundred day moving average of $22.72. The stock has a market capitalization of $2.12 billion, a price-to-earnings ratio of -19.10 and a beta of 0.33.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06). Equities research analysts anticipate that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Insider Activity

In other news, COO Anish Patel sold 48,300 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the sale, the chief operating officer owned 215,011 shares in the company, valued at $6,018,157.89. This trade represents a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the business’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $29.04, for a total transaction of $145,200.00. Following the transaction, the insider directly owned 740,188 shares in the company, valued at approximately $21,495,059.52. The trade was a 0.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 232,180 shares of company stock worth $6,217,033. Company insiders own 25.90% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Enliven Therapeutics by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after acquiring an additional 1,693 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Enliven Therapeutics by 61.3% in the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock valued at $4,167,000 after purchasing an additional 80,506 shares during the last quarter. Jane Street Group LLC purchased a new position in Enliven Therapeutics in the first quarter valued at about $578,000. Geode Capital Management LLC boosted its holdings in Enliven Therapeutics by 7.8% in the second quarter. Geode Capital Management LLC now owns 882,753 shares of the company’s stock valued at $17,711,000 after purchasing an additional 63,580 shares during the last quarter. Finally, Swiss National Bank boosted its holdings in Enliven Therapeutics by 47.8% in the second quarter. Swiss National Bank now owns 61,873 shares of the company’s stock valued at $1,241,000 after purchasing an additional 20,000 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.